2015 Liver Meeting
According to the AASLD, more than 9,500 hepatologists and hepatology health professionals "will gather at The Liver Meeting to exchange the latest liver diseases research, discuss treatment outcomes, and interact with colleagues."
Q&A with Barry Schlansky, MD, from Oregon Health & Science University: Taking a New Look at Liver Transplants for Obese Patients
The annual US cost of HCV treatment before direct-acting antivirals was $7 billion and since then it has grown to $21 billion, but that cost should drop when generics arrive, to $14 million annually by 2030. Making it a rare disease over the next 25 years will take $106 billion, researchers project.
All is not lost when hepatitis C genotype 1 patients fail to benefit from treatment with direct-acting antivirals (DAAs). Reporting at the 2015 Liver Meeting (AASLD) in San Francisco, CA, Fred Poordad, MD, of the Texas Liver Institute/University of Texas Health Science Center in San Antonio, TX, and colleagues said they had success retreating patients who had failed DAAs.
Q&A with Alain Litwin, MD, from Albert Einstein College of Medicine: Studying and Overcoming Stigmas of Treating Injectable Drug Users with Hepatitis C
An estimated 10 million people in China have hepatitis C but the only treatment available there is interferon/ribaviron. Though the drug-approval process in China is slower than in other nations, a phase 3 trial of two Bristol-Myers Squibb direct-acting antivirals has been completed, putting access to DAAs closer.
Q&A with Jagpreet Chhatwal, PhD, from Massachusetts General Hospital: Measuring Costs for Hepatitis C Treatment
Q&A With Lauren Beste From VA Puget Sound Health Care System: Liver Disease A Serious Concern in Veteran Population
Q&A with Melissa Harris from Bristol-Myers Squibb: Expanding Hepatitis C Treatment to New Genotypes and Populations
The high costs of direct-acting antivirals to treat hepatitis C infection is no secret, but neither is the fact that the drugs are cost-effective. Pennsylvania researchers found insurers were lagging in approving payment for the drugs in their four-state region, with Medicaid programs the worst offenders.